On August 4, Odyssey Therapeutics (NASDAQ:ODTX) reported its second-quarter financial results and gave investors a fresh look at where its lead autoimmune drug candidate stands. The clinical-stage biopharmaceutical company said it closed the quarter with $433.1 million in cash, enough to keep the lights on well into 2028, while its RIPK2 inhibitor OD-001 moves toward a fuller data unveiling this fall. The update lands as hedge fund ownership swings sharply and short sellers keep a meaningful stake in the stock.
Two Years Of Runway, Two New Trials
Odyssey’s balance sheet anchors the bull case. The $433.1 million on hand as of June 30, 2026 gives management a runway that stretches into the second half of 2028, more than two years to advance the pipeline without being forced into a rushed capital raise. That cushion matters for a company that still books no product revenue.
The clinical story is also picking up pace. The company finished dosing patients in the Phase 2a expansion cohort for OD-001, its RIPK2 scaffolding inhibitor, and is now working through the complete data set, with results set for an oral slot at United European Gastroenterology Week this October. CEO Gary D. Glick called the earlier proof-of-concept results an important milestone for the company. Odyssey also plans to open two additional studies before year-end: a Phase 2b trial testing OD-001 alone and a Phase 2a trial pairing it with vedolizumab. Behind that program sits OD-002, an oral compound targeting a B-cell pathway called SLC15A4, which is on pace for a clinical trial application by the end of 2026 and a first-in-human study in the first half of 2027, eventually expanding into patients with cutaneous lupus erythematosus among other autoimmune conditions.
Losses Widen As Spending Climbs
The financials show what that progress costs. The quarter’s net loss totaled $52.8 million, up from $41.2 million a year earlier. R&D spending rose to $36.2 million from $30.2 million as the company poured more money into external work on its clinical and preclinical programs. G&A costs moved the other way, falling to $10.5 million from $13.2 million thanks to lower legal and accounting bills, but that saving did not come close to offsetting the R&D increase.
Part of the wider GAAP loss traces back to an $8.7 million non-cash charge from a shift in the fair value of contingent consideration, compared with a small benefit in the same period last year. Backing that out, along with stock-based compensation, adjusted net loss came to $38.4 million, nearly flat against $38.1 million a year earlier. The bigger question for investors is timing: the two newest trials are not expected to produce topline induction data until the second half of 2027, leaving more than a year before the next major clinical checkpoint.
Funds Pile In, Shorts Stick Around
Hedge fund ownership jumped from zero funds in the prior quarter to 24 in the most recent one, a sharp swing toward institutional buying. Short sellers have not stepped back, though, with 5.25% of the float sold short, a level that signals a genuine pocket of skepticism rather than a stock nobody is betting against. Rising fund ownership sitting next to meaningful short interest points to a stock that has become a real point of disagreement heading into October.
The Data Readout That Decides It
Odyssey enters the fall with cash to spare and a pipeline finally running multiple studies at once, even as losses keep growing alongside it. The bulls lean on the funded runway into 2028 and the expanding OD-001 program, plus OD-002’s march toward the clinic. The bears point to the widening net loss and a data wait that stretches into 2027 for the newest trials. October’s presentation of the full Phase 2a data set, expansion cohort included, is the nearest event that could tip that balance.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center